Two previously unrecognized genetic markers may predict whether breast cancer patients would benefit from chemotherapy followed by tamoxifen, according to preclinical research from Roswell Park Cancer Institute (RPCI), in collaboration with the cooperative research group SWOG and St. Jude Children’s Research Hospital.